Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

View Full Paper
Ask AI
Bookmark
Share

Authors

JXJian XuWFWeijun FuYMYueying Mao

Discussion

Loading...

Member takes

Overview

Multicenter trial shows substantial progression-free survival in ultra-high-risk multiple myeloma patients, indicating promise for daratumumab and carfilzomib therapy.

Key Points

  • To evaluate the efficacy and safety of daratumumab plus carfilzomib in ultra high-risk newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation.
  • Multicenter phase 2 trial
  • Transplant-eligible patients aged 18-70 with ultra-high-risk multiple myeloma
  • Daratumumab and carfilzomib based induction, consolidation, and maintenance therapy followed by autologous stem cell transplantation
  • Primary endpoint: 2-year progression-free survival rate
  • Secondary endpoints include overall survival and minimal residual disease negativity
  • 100% overall response rate (ORR) after 1 cycle of induction therapy
  • 86.4% achieved very good partial response (≥VGPR) after 1 cycle
  • Post-ASCT, 71.4% achieved stringent complete response (sCR)
  • The predominant toxicities included neutropenia and infections, manageable with supportive care

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d153https://doi.org/10.1182/blood-2025-5828
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study2025
  2. 2Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis2025
  3. 3Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice2025
  4. 4Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China2025
  5. 5Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study2025